NCT07153172

Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108

Safety Follow-up Study of Participants Previously Dosed With INV-347 in the First-in-Human Study INV-CL-108

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 91 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The study looks at the safety and blood levels of the study drug INV-347 in participants who were previously dosed with INV-347 in study INV-CL-108. Participants will not get any study drug in this study as it looks into the safety of a drug previously dosed. The study will last until visit 21.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	INV-347	Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety.

Timeline

• Start date: 2025-08-06
• Primary completion: 2027-09-15
• Completion: 2027-09-15
• First posted: 2025-09-03
• Last updated: 2026-03-06

Locations

1 site across 1 country: Canada